Clinical Trial

A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Completed Phase 1
View on ClinicalTrials.gov →
Summary
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-25
notable Primary completion moved earlier: 2026-11 -> 2026-05-14 2026-07-25
minor Completion moved earlier: 2027-03 -> 2026-05-14 2026-07-25
Trial Details
NCT Number NCT07284043
Lead Sponsor Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Conditions Hemodialysis Subjects With Secondary Hyperparathyroidism
Enrollment 6 participants
Start Date 2025-11-27
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-05-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-24